Compare GBCI & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GBCI | QURE |
|---|---|---|
| Founded | 1955 | 1998 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 1.9B |
| IPO Year | N/A | 2007 |
| Metric | GBCI | QURE |
|---|---|---|
| Price | $43.89 | $19.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $51.80 | ★ $58.55 |
| AVG Volume (30 Days) | 694.8K | ★ 2.4M |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | ★ 26.70 | N/A |
| EPS | ★ 2.05 | N/A |
| Revenue | ★ $900,148,000.00 | $15,751,000.00 |
| Revenue This Year | $13.46 | N/A |
| Revenue Next Year | $27.84 | $158.05 |
| P/E Ratio | $21.63 | ★ N/A |
| Revenue Growth | ★ 15.35 | N/A |
| 52 Week Low | $36.76 | $7.76 |
| 52 Week High | $56.39 | $71.50 |
| Indicator | GBCI | QURE |
|---|---|---|
| Relative Strength Index (RSI) | 56.80 | 25.66 |
| Support Level | $42.09 | $20.55 |
| Resistance Level | $43.49 | $28.50 |
| Average True Range (ATR) | 1.03 | 1.47 |
| MACD | 0.32 | 0.12 |
| Stochastic Oscillator | 78.76 | 4.43 |
Glacier Bancorp Inc is a regional bank holding company providing commercial banking services to scores of communities through its wholly-owned bank subsidiary, Glacier Bank. The bank operates a multitude of banking offices in Montana, Idaho, Colorado, Utah, Washington, and Wyoming. The bank's various products and services include deposit, loans, and mortgage origination services, among others. The bank predominantly serves individuals, small- to medium-sized businesses, community organizations, and public entities. Glacier emphasizes both internal growth and growth through selective acquisitions. A majority of the bank's loan portfolio is in commercial real estate, while a majority of its net revenue is net interest income.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.